62nd ASH Annual Meeting and Exposition: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: The Role of the Bone Marrow Microenvironment in the Pathogenesis and Therapy of Multiple Myeloma and Waldenstrom’s Macroglobulinemia.

Oral and Poster Abstracts
Oral

Biological, multiple myeloma, Adult, Diseases, smoldering myeloma, Therapies, cell regulation, Biological Processes, B-Cell Lymphoma, Technology and Procedures, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, genetic profiling, genomics, flow cytometry, mass cytometry, NGS, microenvironment, molecular interactions, RNA sequencing, pathogenesis, WGS, pathways, signal transduction

Moderators:

Cyrille Touzeau, Nantes University Hospital and Aldo M. Roccaro, MD, PhD, ASST Spedali Civili di Brescia

Disclosures:

Touzeau: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Roccaro: Janssen: Other; Italian Association for Cancer Research (AIRC): Research Funding; Transcan2-ERANET: Research Funding; European Hematology Association: Research Funding; AstraZeneca: Research Funding; Amgen: Other; Celgene: Other.

2:00 PM

485

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Elisabet E. Manasanch, MD¹, Guangchun Han²^*, Zheng Zhang³^*, Minghao Dang⁴^*, Manisha Singh⁵^*, Maliha Khan, M.D.⁶^*, Shubhra Singh⁴^*, Hans C. Lee, MD¹, Krina K. Patel, M.D.⁷, Gregory P. Kaufman, MD¹^*, Behrang Amini, MD, PhD⁸^*, Qaiser Bashir, MD⁹, Samer A. Srour, MD, MS⁹, Yago Nieto, MD¹⁰, Muzaffar H. Qazilbash, MD¹¹, Zuzana Berkova, Ph.D.¹^*, Pei Lin, MD, DM, MDPC¹²^*, Donald Berry, MD, PhD¹³^*, Sheeba K. Thomas, MD¹, Donna M. Weber, MD¹, P. Andrew Futreal¹⁴^*, Linghua Wang, PhD²^*, Robert Z. Orlowski, MD, PhD³ and Sattva S. Neelapu, MD¹

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
⁴MD ANDERSON CANCER CENTER, HOUSTON, TX
⁵Department of Lymphoma and Myeloma, MD ANDERSON CANCER CENTER, HOUSTON, TX
⁶Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Diagnostic Radiology, University of Texas M.D. Anderson Cancer Center, Houston, TX
⁹Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁰Department of Stem Cell Transplantation and Cellular Therapy, UT M.D. Anderson Cancer Ctr., Houston, TX
¹¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Department of Pathology, M.D. Anderson Cancer Center, Houston, TX
¹³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁴Department of Genomic Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX

2:15 PM

486

Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum

Taxiarchis Kourelis, MD¹, Alissa Visram, MD², Surendra Dasari, PhD³^*, Emilie Anderson, M.S.⁴^* and Shaji K. Kumar, MD¹

¹Mayo Clinic Rochester, Division of Hematology, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Department of Health Sciences Research, Mayo Clinic, Rochester, MN
⁴Mayo Clinic, Rochester, MN

2:30 PM

487

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Chandraditya Chakraborty, PhD¹^*, Eugenio Morelli, MD², Srikanth Talluri, PhD³^*, Sanika Derebail, MS⁴^*, Yan Xu, MD⁵^*, Yao Yao⁶^*, María Linares⁷^*, Alba Rodríguez García^7,8^*, Kenneth Anderson, MD^5,9, Mehmet Kemal Samur, PhD¹⁰^*, Mariateresa Fulciniti, PhD¹¹ and Nikhil C. Munshi, MD¹⁰

¹Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Medical Oncology, DANA FARBER CANCER INSTITUTE, Boston, MA
³The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, West Roxbury, MA
⁴Dana-Farber Cancer Institute, Boston, MA
⁵The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Dana Farber Cancer Institute, Boston, MA
⁷Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, Madrid, Spain
⁸Hospital12 de Octubre, Complutense University of Madrid, Madrid, Spain
⁹Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

2:45 PM

488

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Alexander Vdovin^1,2,3^*, Michal Durech, PhD^1,2^*, Tomas Jelinek^1,4^*, Tereza Sevcikova, PhD^1,2,3^*, Juli R. Bago^4,5^*, Matous Hrdinka, PhD^1,2^*, David Zihala^4,5^*, Renata Snaurova^1,2,3^*, Hana Sahinbegovic^1,2,3^*, Tereza Popkova^3,5^*, Ryszard Smolarczyk, PhD⁶^*, Tomasz Cichon, PhD⁶^*, Sebastian Giebel, MD PhD⁷^*, Roman Hajek, MD, PhD^1,2 and Michal Simicek, PhD^1,2,3^*

¹Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
²Faculty of Medicine, Department of Clinical Studies, University of Ostrava, Ostrava, Czech Republic
³Faculty of Science, University of Ostrava, Ostrava, Czech Republic
⁴Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
⁵Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
⁶Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
⁷Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

3:00 PM

489

Waldenström’s Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Sara Rodríguez, PhD¹^*, Cirino Botta, MD, PhD², Jon Celay, PhD³^*, Ibai Goicoechea, PhD³, Cristina Jiménez, PhD⁴^*, Maria J Garcia-Barchino, PhD³^*, Rafael Valdés-Mas⁵^*, Yolanda Carrasco⁶^*, Juan José Garcés³^*, Marta Larrayoz, PhD³^*, Susana Santos⁷^*, Diego Alignani, PhD³^*, Amaia Vilas-Zornoza, PhD³^*, Cristina Pérez Ruiz³^*, Sonia Garate³^*, Sarvide Sarai³^*, Aitziber Lopez Lopez³^*, Christian Reinhardt, MD⁸^*, Isidro Sanchez-Garcia, PhD⁴^*, Maria Jose Larrayoz, BSc³^*, María José Calasanz, PhD³^*, Felipe Prosper, MD³^*, Marina Motta, MD⁹^*, Giuseppe Rossi, MD⁹, Antonio Sacco, RN⁹^*, Massimo Gentile¹⁰^*, Sara Duarte⁷^*, Helena Vitoria⁷^*, Catarina Geraldes, MD, PhD⁷^*, Artur Paiva⁷^*, Ramón Garcia-Sanz, MD, PhD⁴, Aldo M. Roccaro, MD, PhD⁹, Jesus F. San-Miguel, MD, PhD³, Jose Angel Martinez-Climent, MD, PhD³^* and Bruno Paiva, PhD³^*

¹Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, PAMPLONA, Spain
²Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy
³Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
⁴Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
⁵Dreamgenics, Oviedo, ESP
⁶Centro Nacional De Biotecnología/Csic, Madrid, ESP
⁷Unidade de Gestão Operacional em Citometria, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal, Coimbra, Portugal
⁸Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital of Cologne, Koeln, Germany
⁹Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
¹⁰Hematology Unit and Biotechnology Research Unit, A.O. of Cosenza, Cosenza, Italy

3:15 PM

490

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom’s Macroglobulinemia By Silencing MYD88

Antonio Sacco, RN¹^*, Cinzia Federico, PhD²^*, Arianna Giacomini, PhD³^*, Cinzia Caprio, PhD²^*, Federica Maccarinelli, PhD³^*, Katia Todoerti, PhD^4,5^*, Vanessa Favasuli^4,6^*, Antonella Anastasia, MD¹^*, Marina Motta, MD¹^*, Giuseppe Rossi, MD¹, Nicole Bozza, PhD⁷^*, Riccardo Castelli, PhD⁷^*, Antonino Neri, MD^4,6, Roberto Ronca, PhD³^*, Chiara Cattaneo, MD¹^*, Alessandra Tucci, MD¹^*, Marco Mor, PhD⁷^*, Marco Presta, PhD³^* and Aldo M. Roccaro, MD, PhD²

¹Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
²Clinical Research Development and Phase I Unit; CREA Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
³Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
⁴Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
⁵BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
⁶Deparment of Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
⁷Department of Food and Drug, University of Parma, Parma, Italy

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O2.6 651. Myeloma: Biology and Pathophysiology, excluding Therapy: The Role of the Bone Marrow Microenvironment in the Pathogenesis and Therapy of Multiple Myeloma and Waldenstrom’s Macroglobulinemia.